After suspending visiting earlier in the year, we are now able to offer limited visiting to some wards at the discretion of the nurse in-charge.”
We recognise the impact that a long stay in hospital can have on families and the importance of maintaining strong communication. Our ward staff are keeping in touch with patients’ next of kin directly and our Patient Advice and Liaison Service (PALS) can help pass on personal messages from family and friends.
The Queen Alexandra Hospital is located just on the hill slopes of Portsdown Hill overlooking Portsmouth. It is conveniently situated for both the M27 and A3M.
Family members and carers play an important role in supporting patients during an episode of ill health. We are committed to the active involvement of family members, friends and carers during a hospital stay. Family members and carers play an important role in supporting patients during an episode of ill health.
More information on visiting hospital for an appointment.
If you've had experience of using our services and would like to make a comment then please contact the Patient Advice and Liaison Service (PALS). Your views are very important to us and we would like to hear where you think improvements are needed or where things have gone so well that you would like to share your thanks or gratitude with the staff involved. When things have not gone so well then you can be sure that we want to hear from you, so please get in touch with PALS.
During your stay in hospital you will meet a number of different members of staff. All members of staff wear name badges, but if you are not sure who someone is or what they do, please feel free to ask them to introduce themselves and explain what they do.
If you have any questions about your treatment, please ask a doctor or a nurse.
There are lots of opportunities for you to get involved with the Trust, from volunteering to attending our public meetings, our Annual General Meeting or our hospital open day which is held every year.
We welcome and value your feedback and use the views you share with us in a number of ways to learn and make improvements as well as sharing best practice. Feedback can be provided in a number of ways.
Date: 10 May 2022
Fourth COVID-19 vaccine dose provides stronger immunity boost than third dose, shows study ran in Portsmouth
COVID-19 vaccines given as fourth doses in the UK offer excellent boosting immunity protection, according to the latest results from a nationwide NIHR-supported study.
The latest results from the COV-BOOST trial, ran at the Portsmouth Research Hub, part of Portsmouth Hospitals University NHS Trust (PHU), Ashow that a fourth dose mRNA vaccine is safe and boosts antibody levels - higher than that of a third dose.
Researchers have published their findings today in The Lancet Infectious Diseases.
Fourth doses of COVID-19 vaccines have been offered as a spring booster for those most vulnerable in the UK. This has been a precautionary strategy to maintain high levels of immunity prior to the study data being available. A wider group of people may be offered a fourth dose booster later this year.
The latest findings show that fourth dose mRNA booster vaccines for COVID-19 are well-tolerated in people who received Pfizer as a third dose. They are also effective at increasing both antibody and cellular immunity up to and above baseline and peak levels observed following third dose boosters.
Professor Saul Faust, trial lead and Director of the NIHR Southampton Clinical Research Facility, said:
“These results underline the benefits of the most vulnerable people receiving current spring boosters and gives confidence for any prospective autumn booster programme in the UK, if the Joint Committee on Vaccination and Immunisation considers it needed at that time.”
Health and Social Care Secretary Sajid Javid, said:
“This is further evidence underlining the importance of people coming forward for their booster as soon as they are eligible.
“We’re able to live with Covid thanks to the protection provided by our phenomenal vaccine programme and a booster dose will top up your immunity to continue to keep you and your loved ones safe.”
Professor Lucy Chappell, Chief Scientific Adviser for the Department of Health and Social Care, Professor of Obstetrics at King’s College London and NIHR Chief Executive, said:
“These results show the benefits of having a fourth COVID-19 booster dose for those eligible, to top-up immunity.
“It is important to recognise the achievement of the COV-Boost study team, participants and all involved who have helped deliver this research to inform the best use of COVID-19 booster vaccines in the UK.
“The COV-Boost study, commissioned through the NIHR, is continuing to deliver world-leading research on booster vaccination.”
The COV-BOOST study, led by University Hospital Southampton, provided the world’s first data on the safety, immune responses and side-effects of third dose in mix and match schedules. The study was key to shaping the UK’s autumn booster programme and gives vital evidence for global vaccination efforts.
In the fourth dose study, across 10 UK sites, 166 people who had received a third dose of Pfizer, following Pfizer or AstraZeneca initial doses in June 2021, were randomised to receive full dose Pfizer or half dose Moderna as a fourth dose. These were approximately seven months after their third dose.
Dr Alexander Hicks, consultant respiratory physician at PHU and local investigator for the trial said: “I would like to thank our participants from Portsmouth and the surrounding communities for helping with this study.
“Once again, we can be reassured that Covid 19 vaccines are safe to use and helpfully this study shows that fourth doses continue to effectively boost our immune systems.
“Going forwards this new evidence will be invaluable in informing decisions for any future booster programs.”
While pain at vaccination site and fatigue were the most common side effects, there were no vaccine-related serious adverse events and fourth doses were safe and well tolerated.
The two vaccines trialled in the fourth dose sub-study were those deployed in the UK NHS third dose booster campaign:
Professor Andrew Ustianowski, NIHR Clinical Lead for the COVID-19 Vaccination Programme and Joint National Infection Specialty Lead said:
"The COV-BOOST study has continuously supported the UK's booster vaccination programme and had further impact on how vaccines are administered globally. The study's latest results once again show the importance of sustained research into COVID-19 vaccines and how they are best used to keep the virus at bay.
“We knew that it was important to offer a fourth dose to those most vulnerable earlier in the year. These new study findings support that decision and provides the public with the confidence that fourth doses are both safe and even more effective than 3rd doses at boosting immunity against COVID-19.
"It is thanks to the endless efforts and contribution of study participants and staff across the UK that we can keep discovering more about the use of vaccines, and they continue to play a pivotal role just as they have done throughout the pandemic."
Current COV-BOOST sub-studies are investigating the interval between second and third doses, fourth doses of mRNA vaccines, an omicron variant vaccine and fractional dosing in young people aged 18-30 years.